Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6

Ejemplares similares